Ryvu Therapeutics SA (RVU) Stock Statistics & Valuation Metrics

Ryvu Therapeutics SA has a market cap or net worth of zł544.48M. The enterprise value is zł556.59M.

Ryvu Therapeutics SA has 23,120,148 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ryvu Therapeutics SA’s return on equity (ROE) is -1.88 and return on invested capital (ROIC) is -74.78%.

The current PE Ratio of Ryvu Therapeutics SA is ―. Ryvu Therapeutics SA’s PEG ratio is 0.68.

In the last 12 months, Ryvu Therapeutics SA had revenue of 62.25M and earned -101.23M in profits. Earnings per share was -4.38.

In the last 12 months, operating cash flow was -112.67M and capital expenditures -7.47M, giving a free cash flow of -120.14M billion.

Ryvu Therapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―

Ryvu Therapeutics SA upcoming earnings date is May 20, 2026, TBA (Confirmed).

Ryvu Therapeutics SA as a current ratio of 2.26, with Debt / Equity ratio of 133.22%

In the past 12 months, Ryvu Therapeutics SA has paid 88.00K in taxes.

Ryvu Therapeutics SA EV to EBITDA ratio is -5.67, with an EV/FCF ratio of -5.42.

Ryvu Therapeutics SA has zł107.68M in cash and marketable securities with zł71.72M in debt, giving a net cash position of zł35.96M billion.

Gross margin is -47.10%, with operating margin of -196.22%, and net profit margin of -162.61%.

The average price target for Ryvu Therapeutics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―